Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Younger Men With Advanced Prostate Cancer Have Shorter Survival Times
While young men with prostate cancer have a low risk of dying early, those with advanced forms of cancer do not live as long as older men with similar forms of the disease. That is the conclusion of a new study published in the July 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society. The paradoxical findings indicate that there may be biological differences between prostate cancers that develop in younger men and those that develop in older men, and that uncovering these differences may help tailor screening and treatment strategies for patients based on age.
generic viagra online
St. Jude Medical Announces European Approval Of Accent RF And Anthem RF Pacemakers Equipped With Wireless Technology
St. Jude Medical, Inc. (NYSE:STJ) announced European CE Mark approval of its Accent™ RF pacemaker and Anthem™ RF CRT-P (cardiac resynchronization therapy pacemaker).
News of the day
Tales Of Health Insurance Plights Highlight Overhaul Efforts
Analysts say many in America take jobs they otherwise wouldn"t simply for the health insurance coverage, Reuters/Boston Globe reports. "It is a situation most Europeans, Canadians and others who enjoy national health services would find bewildering if not appalling and is one factor fueling the drive to reform the hugely expensive U.S. healthcare system. ò€¦ U.S. company healthcare plans are usually subsidized by the employer. They are much more affordable and comprehensive than private plans that can exceed a $1,000 a month for a family, a huge burden for most households."
Medical Devices

Measurements Fail To Identify TB Patients Who Could Benefit From Shorter Treatment Course

Tuberculosis (TB) is a difficult infection to treat and requires six months of multiple antibiotics to cure it. To combat the TB pandemic, a shorter and simpler drug treatment would be a huge advance since most TB occurs in re-limited settings with poor public health infrastructures. Testing whether two simple clinical measurements might help identify which TB patients could benefit from shorter treatment, researchers at Case Western Reserve University and University Hospitals (UH) Case Medical Center report that these measurements failed to work in a study published online by the American Journal of Respiratory and Critical Care Medicine. The two measurements were absence of a cavity (an abscess caused by TB) in the lungs (detected by chest X-ray) and failure to grow TB bacteria from the sputum once drug treatment was started (sputum culture conversion). The Phase III clinical trial involved TB patients in Uganda (Africa), Brazil (S. America) and the Philippines (Asia) and was conducted by the Tuberculosis Research Unit (TBRU) at Case Western Reserve University and UH Case Medical Center in Cleveland, the only National Institutes of Health supported TB unit in the U.S. "We found that combining these two clinical measurements failed to select TB patients who could benefit from shorter drug treatment. TB patients receiving four months of TB treatment had their disease come back much more often than those who got six months of drug treatment," said W. Henry Boom, M.D., an infectious disease expert with Case Western Reserve University and UH Case Medical Center and Director of the TBRU. "This study points out the limitations of current clinical measures to identify the relatively small group of TB patients who respond poorly to standard drug treatment." "To better identify risk factors for why treatment fails in a subset of TB patients will require novel approaches and further research so that we can determine quickly (not having to wait for two years after completing six months of drug treatment to measure relapses) not only the effectiveness of new TB drugs or regimens but also who will benefit most from these shortened and simplified TB treatment regimens," added John L. Johnson, MD, first author of the study and an infectious disease expert with Case Western Reserve University School of Medicine and UH Case Medical Center. The TBRU is a clinical research contract funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Contact: Alicia Reale University Hospitals Case Medical Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009